Special section on DMPK of therapeutic proteins - Minireview: Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins

Drug Metabolism and Disposition

Volumn 42, Issue 11, 2014, Pages 1890-1905

  Kagan, Leonid ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; ALPHA2B INTERFERON; AMYLOID BETA PROTEIN ANTIBODY; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN G2A; INSULIN; INTERLEUKIN 10; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TRASTUZUMAB;

ANALYSIS OF COVARIANCE; BIOLOGICAL THERAPY; BLOOD; CAPILLARY; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG UPTAKE; DUAL PATHWAY ABSORPTION MODEL; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LYMPH; MICHAELIS MENTEN KINETICS; MODEL; NONHUMAN; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; SHORT SURVEY; SINGLE PATHWAY ABSORPTION MODEL; SKIN ABSORPTION; SPECIES COMPARISON; SPECIES DIFFERENCE; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; BIOLOGICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; HUMANS; INFUSIONS, SUBCUTANEOUS; INSULIN; MODELS, BIOLOGICAL; PROTEINS; SKIN ABSORPTION;

EID: 84929079436     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059121     Document Type: Short Survey

References (152)

1. Abe S, Chiba K, and Suwa T (2013) Low-molecular-weight heparin pharmacokinetics: a dual absorption model approach. Int J Clin Pharmacol Ther 51:482-489.
2. Abraham AK, Mager DE, Gao X, Li M, Healy DR, and Maurer TS (2009) Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans. J Pharmacol Exp Ther 330:169-178.
3. Agoram B, Sutjandra L, and Sullivan JT (2007) Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol 63:41-52.
4. Antohe F, Rǎdulescu L, Gafencu A, Gheţie V, and Simionescu M (2001) Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 62:93-105.
5. Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, and Wiestner A (2010) Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 95:329-332.
6. Baxter LT, Zhu H, Mackensen DG, Butler WF, and Jain RK (1995) Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55:4611-4622.
7. Baxter LT, Zhu H, Mackensen DG, and Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517-1528.
8. Beals JM, DeFelippis MR, Kovach PM, and Jackson JA (2013) Insulin, in Pharmaceutical Biotechnology: Fundamentals and Applications (Crommelin DJA, Sindelar RD, and Meibohm B eds) pp 255-276, Springer, New York.
9. Beck A, Wurch T, Bailly C, and Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345-352.
10. Berger M and Rodbard D (1989) Computer simulation of plasma insulin and glucose dynamics after subcutaneous insulin injection. Diabetes Care 12:725-736.
11. Beshyah SA, Anyaoku V, Niththyananthan R, Sharp P, and Johnston DG (1991) The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clin Endocrinol (Oxf) 35:409-412.
12. Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, and Schmidt J (2012) Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung 62:401-409.
13. Bittner B and Schmidt J (2012) Subcutaneous administration of monoclonal antibodies in oncology as alternative to established intravenous infusion: a review. Pharm Ind (Pharmind) 74:638-643.
14. Bocci V, Muscettola M, Naldini A, Bianchi E, and Segre G (1986) The lymphatic route - II. Pharmacokinetics of human recombinant interferon-alpha 2 injected with albumin as a retarder in rabbits. Gen Pharmacol 17:93-96.
15. Bocci V, Pacini A, Pessina GP, Maioli E, and Naldini A (1987) Studies on tumor necrosis factor (TNF) - I. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administration. Gen Pharmacol 18:343-346.
16. Bocci V, Pessina GP, Nicoletti C, and Paulesu L (1990) The lymphatic route. VII. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph. J Biol Regul Homeost Agents 4:25-29.
17. Bocci V, Pessina GP, Paulesu L, Muscettola M, and Valeri A (1988a) The lymphatic route. V. Distribution of human natural interferon-beta in rabbit plasma and lymph. J Interferon Res 8:633-640.
18. Bocci V, Pessina GP, Paulesu L, and Nicoletti C (1988b) The lymphatic route. VI. Distribution of recombinant interferon-alpha 2 in rabbit and pig plasma and lymph. J Biol Response Mod 7:390-400.
19. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, and Frost GI (2006) A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114:230-241.
20. Brange J, Owens DR, Kang S, and Vølund A (1990) Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954.
21. Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, and Roy S (2012) Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet 51:e1-e18.
22. Chakraborty A, Van LM, Skerjanec A, Floch D, Klein UR, Krammer G, Sunkara G, and Howard D (2013) Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. J Clin Pharmacol 53:1240-1251.
23. Charman SA, McLennan DN, Edwards GA, and Porter CJ (2001) Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm Res 18:1620-1626.
24. Charman SA, Segrave AM, Edwards GA, and Porter CJ (2000) Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J Pharm Sci 89:168-177.
25. Chatelut E, Rostaing L, Grégoire N, Payen JL, Pujol A, Izopet J, Houin G, and Canal P (1999) A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol 47:365-371.
26. Chen T, Mager DE, and Kagan L (2013) Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res 30:751-760.
27. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, and Weinstein JN (1986) Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 46:3969-3978.
28. Dahlberg AM, Kaminskas LM, Smith A, Nicolazzo JA, Porter CJ, Bulitta JB, and McIntosh MP (2014) The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. Mol Pharm 11:496-504.
29. Datta-Mannan A, Witcher DR, Lu J, and Wroblewski VJ (2012) Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs 4:267-273.
30. Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, Berge C, Bittner B, Boehnke A, and McIntyre C, et al. (2014) Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 15:343-352.
31. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, and Prabhu S (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? MAbs 3:61-66.
32. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, and Prabhu S (2010) Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-alpha antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 38:600-605.
33. Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder PJ, and Prabhu S (2012) Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs 4:101-109.
34. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS, and Lencer WI (1999) Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104:903-911.
35. Dirks NL and Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659.
36. Doshi S, Chow A, and Pérez Ruixo JJ (2010) Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. J Clin Pharmacol 50(9, Suppl)75S-90S.
37. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, and Chetty M (2013) Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 52:83-124.
38. Dychter SS, Gold DA, and Haller MF (2012) Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs. J Infus Nurs 35:154-160.
39. Fang Y, Li LJ, Wang R, Huang F, Song HF, Tang ZM, Li YZ, Guan HS, and Zheng QS (2010) Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis. Acta Pharmacol Sin 31:1500-1507.
40. Fineman M, Phillips L, Jaworowicz DJ, Cirincione B, Ludwig E, Taylor K, Kothare PA, Baron AD, and Grasela T (2007) Model-based evaluations to select and confirm doses in the clinical development of exenatide, poster presentation at the American Society for Clinical Pharmacology and Therapeutics; 2007 March 21-24; Anaheim, CA. American Society for Clinical Pharmacology and Therapeutics, Alexandria, VA. http://www.cognigencorp.com/perspective/presentationsinternet.kp/44/443.html.
41. Frost GI (2007) Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4:427-440.
42. Gao W and Jusko WJ (2012) Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab Dispos 40:990-997.
43. Garg A and Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687-709.
44. Gershkovich P, Kagan L, and Hoffman A (2007) Lymphatic absorption of nanoparticles, in Nanoparticles for Pharmaceutical Applications (Domb AJ, Tabata Y, Ravi Kumar MNV, and Farber S eds), pp 167-176, American Scientific Publishers, Valencia, CA.
45. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, and Ward ES (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690-696.
46. Gibiansky L, Gibiansky E, Kakkar T, and Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573-591.
47. Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, and Pérez-Ruixo JJ (2012) Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 51:247-260.
48. Gibney MA, Arce CH, Byron KJ, and Hirsch LJ (2010) Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin 26:1519-1530.
49. Goggin T, Nguyen QT, and Munafo A (2004) Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer. Br J Clin Pharmacol 57:576-585.
50. Gopalakrishnan M, Suarez S, Hickey AJ, and Gobburu JV (2005) Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. J Pharmacokinet Pharmacodyn 32:485-500.
51. Hansen RJ and Balthasar JP (2003) Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92:1206-1215.
52. Hayashi N, Tsukamoto Y, Sallas WM, and Lowe PJ (2007) A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 63:548-561.
53. Hoffman A and Ziv E (1997) Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet 33:285-301.
54. Hu C, Xu Z, Zhang Y, Rahman MU, Davis HM, and Zhou H (2011) Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. J Clin Pharmacol 51:639-648.
55. Jain RK and Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48:7022-7032.
56. Janowitz T (2011) Biopharmaceuticals and monoclonal antibodies in oncology trials - a cross-sectional analysis. Protein Eng Des Sel 24:105-111.
57. Jensen JD, Jensen LW, and Madsen JK (1994) The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 46:333-337.
58. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, and Greway T (2005) Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 24:465-475.
59. Junghans RP and Anderson CL (1996) The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512-5516.
60. Kagan L, Abraham AK, Harrold JM, and Mager DE (2010) Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 27:920-932.
61. Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, and Hoffman A (2007) The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm 67:759-765.
62. Kagan L and Mager DE (2013) Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos 41:248-255.
63. Kagan L, Turner MR, Balu-Iyer SV, and Mager DE (2012) Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 29:490-499.
64. Kagan L, Zhao J, and Mager DE (2014) Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res DOI:[published ahead of print].
65. Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, Vincent M, Banfield C, Colbert A, and Hoofring S, et al. (2011) Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res 28:2530-2542.
66. Kinnunen HM and Mrsny RJ (2014) Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site. J Control Release 182:22-32.
67. Klitgaard T, Nielsen JN, Skettrup MP, Harper A, and Lange M (2009) Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. Growth Horm IGF Res 19:463-470.
68. Knebel W, Palmen M, Dowell JA, and Gastonguay M (2008) Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. J Clin Pharmacol 48:837-848.
69. Kobayashi T, Sawano S, Itoh T, Kosaka K, Hirayama H, and Kasuya Y (1983) The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients. Diabetes 32:331-336.
70. Kota J, Machavaram KK, McLennan DN, Edwards GA, Porter CJ, and Charman SA (2007) Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos 35:2211-2217.
71. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, and Cheung WK (2005) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 26:295-306.
72. Krzyzanski W, Wiczling P, Lowe P, Pigeolet E, Fink M, Berghout A, and Balser S (2010) Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. J Clin Pharmacol 50(9, Suppl)101S-112S.
73. Landersdorfer CB, Bexon M, Edelman J, Rojavin M, Kirkpatrick CM, Lu J, Pfister M, and Sidhu J (2013) Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. Postgrad Med 125:53-61.
74. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, and Peck CC (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348-365.
75. Lehmann ED, Tarín C, Bondia J, Teufel E, and Deutsch T (2009) Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 3. Early plasma insulin determinations. J Diabetes Sci Tech 3:190-201.
76. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
77. Lin JH (2009) Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab 10:661-691.
78. Lindena J, Küpper W, and Trautschold I (1986) Catalytic enzyme activity concentration in thoracic duct, liver, and intestinal lymph of the dog, the rabbit, the rat and the mouse. Approach to a quantitative diagnostic enzymology, II. Communication. J Clin Chem Clin Biochem 24:19-33.
79. Lindstedt SL and Schaeffer PJ (2002) Use of allometry in predicting anatomical and physiological parameters of mammals. Lab Anim 36:1-19.
80. Ling J, Zhou H, Jiao Q, and Davis HM (2009) Interspecies scaling of therapeutic monoclonal antibodies: Initial look. J Clin Pharmacol 49:1382-1402.
81. Liu D, Lon HK, Dubois DC, Almon RR, and Jusko WJ (2011) Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. J Pharmacokinet Pharmacodyn 38:769-786.
82. Lowe PJ, Tannenbaum S, Gautier A, and Jimenez P (2009) Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68:61-76.
83. Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, and Williams JD (1991) Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol 88:152-156, discussion 157-158.
84. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
85. Mager DE and Jusko WJ (2002) Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-β 1a in humans. Pharm Res 19:1537-1543.
86. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, and Jusko WJ (2003) Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther 306:262-270.
87. Mager DE, Neuteboom B, and Jusko WJ (2005) Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 22:58-61.
88. Mahmood I (2004) Interspecies scaling of protein drugs: Prediction of clearance from animals to humans. J Pharm Sci 93:177-185.
89. Mahmood I (2009) Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci 98:3850-3861.
90. McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, and Ivens IA (2010) Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther 12:461-470.
91. McLennan DN, Porter CJ, Edwards GA, Brumm M, Martin SW, and Charman SA (2003) Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. Pharm Res 20:1156-1162.
92. McLennan DN, Porter CJ, Edwards GA, Heatherington AC, Martin SW, and Charman SA (2006) The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. Pharm Res 23:2060-2066.
93. McLennan DN, Porter CJ, Edwards GA, Martin SW, Heatherington AC, and Charman SA (2005a) Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther 313:345-351.
94. McLennan DN, Porter CJH, and Charman SA (2005b) Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol 2:89-96.
95. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, and Ochs HD (2009) Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 158 (Suppl 1):51-59.
96. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, and Green JD (1991) Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359.
97. Mosekilde E, Jensen KS, Binder C, Pramming S, and Thorsteinsson B (1989) Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17:67-87.
98. Naik H, Tsai MC, Fiedler-Kelly J, Qiu P, and Vakilynejad M (2013) A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. PLoS ONE 8:e66422.
99. Nestorov I, Zitnik R, and Ludden T (2004) Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn 31:463-490.
100. Ng CM, Joshi A, Dedrick RL, Garovoy MR, and Bauer RJ (2005) Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22:1088-1100.
101. Nieforth KA, Nadeau R, Patel IH, and Mould D (1996) Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 59:636-646.
102. Nucci G and Cobelli C (2000) Models of subcutaneous insulin kinetics. A critical review. Comput Methods Programs Biomed 62:249-257.
103. Ober RJ, Radu CG, Ghetie V, and Ward ES (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13:1551-1559.
104. Olsson-Gisleskog P, Jacqmin P, and Perez-Ruixo JJ (2007) Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet 46:159-173.
105. Porter CJ and Charman SA (2000) Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89:297-310.
106. Porter CJ, Edwards GA, and Charman SA (2001) Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev 50:157-171.
107. Potocka E, Baughman RA, and Derendorf H (2011) Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol 51:1015-1024.
108. Puckett WR and Lightfoot EN (1995) A model for multiple subcutaneous insulin injections developed from individual diabetic patient data. Am J Physiol 269:E1115-E1124.
109. Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, and Jusko WJ (1998) Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res 15:1895-1901.
110. Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, and Zampaglione N (1987) Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 27:432-435.
111. Ramakrishnan R, Cheung WK, Farrell F, Joffee L, and Jusko WJ (2003) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 306:324-331.
112. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, and Jusko WJ (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 44:991-1002.
113. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413-415.
114. Richter WF, Bhansali SG, and Morris ME (2012) Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14:559-570.
115. Segrave AM, Mager DE, Charman SA, Edwards GA, and Porter CJ (2004) Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther 309:1085-1092.
116. Shah DK, Missmer SA, Correia KF, and Ginsburg ES (2014) Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab 99:1314-1321.
117. Sun YN, Lee HJ, Almon RR, and Jusko WJ (1999) A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. J Pharmacol Exp Ther 289:1523-1532.
118. Sun YN, Lu JF, Joshi A, Compton P, Kwon P, and Bruno RA (2005) Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 45:468-476.
119. Supersaxo A, Hein W, Gallati H, and Steffen H (1988) Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm Res 5:472-476.
120. Supersaxo A, Hein WR, and Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167-169.
121. Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, Chow AT, and Pérez-Ruixo JJ (2011) Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 50:793-807.
122. Swartz MA (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50:3-20.
123. Tarín C, Teufel E, Picó J, Bondia J, and Pfleiderer HJ (2005) Comprehensive pharmacokinetic model of insulin Glargine and other insulin formulations. IEEE Trans Biomed Eng 52:1994-2005.
124. ter Braak EW, Woodworth JR, Bianchi R, Cerimele B, Erkelens DW, Thijssen JH, and Kurtz D (1996) Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 19:1437-1440.
125. Tobinai K (2014) Subcutaneous rituximab: a practical approach? Lancet Oncol 15:254-255.
126. Trajanoski Z, Wach P, Kotanko P, Ott A, and Skraba F (1993) Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues. Biomed Tech (Berl) 38:224-231.
127. Velagapudi R, Noertershauser P, Awni W, Granneman R, and Kupper H (2005) Bioavailability of adalimumab following subcutaneous injections in rheumatoid arthritis patients. Clin Pharmacol Ther 77:P84 DOI: .
128. Vora JP, Burch A, Peters JR, and Owens DR (1992) Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care 15:1484-1493.
129. Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917-924.
130. Wang W and Prueksaritanont T (2010) Prediction of human clearance of therapeutic proteins: Simple allometric scaling method revisited. Biopharm Drug Dispos 31:253-263.
131. Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K, Wang B, Hong X, Adreani C, and Nunes CN, et al. (2012) Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos 40:952-962.
132. Wang W, Wang EQ, and Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548-558.
133. Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Pérez-Ruixo JJ, and Chow AT (2010) Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J 12:729-740.
134. Watts MJ, Addison I, Long SG, Hartley S, Warrington S, Boyce M, and Linch DC (1997) Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 98:474-479.
135. Wiczling P, Lowe P, Pigeolet E, Lüdicke F, Balser S, and Krzyzanski W (2009) Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin Pharmacokinet 48:817-826.
136. Wong J, Chase JG, Hann CE, Shaw GM, Lotz TF, Lin J, and Le Compte AJ (2008) A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: model structure and parameter identification. J Diabetes Sci Tech 2:658-671.
137. Woo S and Jusko WJ (2007) Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos 35:1672-1678.
138. Woo S, Krzyzanski W, and Jusko WJ (2006) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther 319:1297-1306.
139. Wu F, Bhansali SG, Law WC, Bergey EJ, Prasad PN, and Morris ME (2012) Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res 29:1843-1853.
140. Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, Baker D, Beutler A, Pendley C, and Wagner C, et al. (2009) Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol 49:1056-1070.
141. Xu Z, Wang Q, Zhuang Y, Frederick B, Yan H, Bouman-Thio E, Marini JC, Keen M, Snead D, and Davis HM, et al. (2010a) Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol 50:276-284.
142. Xu ZH, Lee H, Vu T, Hu C, Yan H, Baker D, Hsu B, Pendley C, Wagner C, and Davis HM, et al. (2010b) Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther 48:596-607.
143. Yan X, Mager DE, and Krzyzanski W (2010) Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37:25-47.
144. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, and Lee H (2005) Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 45:246-256.
145. Zhao L, Ji P, Li Z, Roy P, and Sahajwalla CG (2013) The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol 53:314-325.
146. Zheng Y, Scheerens H, Davis JC, Jr, Deng R, Fischer SK, Woods C, Fielder PJ, and Stefanich EG (2011) Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin Pharmacol Ther 89:283-290.
147. Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, and Fielder PJ, et al. (2012) Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs 4:243-255.
148. Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, and Zhou H (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49:162-175.
149. Zhu YW, Mendelsohn A, Pendley C, Davis HM, and Zhou H (2010) Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. Int J Clin Pharmacol Ther 48:830-846.
150. Zhuang Y, Xu Z, de Vries DE, Wang Q, Shishido A, Comisar C, Ford JA, Keen M, Achira M, and Tsukamoto Y, et al. (2013) Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int J Clin Pharmacol Ther 51:187-199.
151. Zierhut ML, Gastonguay MR, Martin SW, Vicini P, Bekker PJ, Holloway D, Leese PT, and Peterson MC (2008) Population PK-PD model for Fc-osteoprotegerin in healthy post-menopausal women. J Pharmacokinet Pharmacodyn 35:379-399.
152. Zou Y, Bateman TJ, Adreani C, Shen X, Cunningham PK, Wang B, Trinh T, Christine A, Hong X, and Nunes CN, et al. (2013) Lymphatic absorption, metabolism, and excretion of a therapeutic peptide in dogs and rats. Drug Metab Dispos 41:2206-2214.